# Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse

> **NCT03779230** · PHASE1,PHASE2 · COMPLETED · sponsor: **Philogen S.p.A.** · enrollment: 20 (actual)

## Conditions studied

- Glioma of Brain

## Interventions

- **DRUG:** L19TNF

## Key facts

- **NCT ID:** NCT03779230
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-31
- **Primary completion:** 2023-06-27
- **Final completion:** 2023-06-27
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03779230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03779230, "Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT03779230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*